The U.S. Food and Drug Administration approved FoundationOne Liquid CDx, a new pan-tumor liquid biopsy test that is indicated for use as a companion diagnostic for four FDA-approved precision therapies.
South San Francisco-based Freenome closed on an oversubscribed $270 million Series C financing, with the round led by new investor Bain Capital Life Sciences and existing investor Perceptive Advisors.
Thrive Earlier Detection, headquartered in Cambridge, Massachusetts, closed on a Series B financing worth $257 million.
Cambridge, Massachusetts-based Thrive Earlier Detection released data from the DETECT-A study evaluating the company’s blood test to screen for multiple types of cancers. The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.
Business updates for various pharma and life science companies around the globe.
Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
Barring a last-minute reversal, 2018 will likely end as a down year for the biotech industry, at least in terms of stock performance.